Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Satricabtagene autoleucel |
| Trade Name | |
| Synonyms | CT-041|CT 041|CT041|satri-cel |
| Drug Descriptions |
Satricabtagene autoleucel (CT041) are autologous T-cells engineered to express a chimeric antigen receptor (CAR) targeting Claudin 18.2 (CLDN18.2), which may inhibit tumor growth (PMID: 30203099, PMID: 35534566). |
| DrugClasses | CLDN18.2 Immune Cell Therapy 4 |
| CAS Registry Number | NA |
| NCIT ID | C150382 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Satricabtagene autoleucel | Satricabtagene autoleucel | 0 | 1 |
| Satricabtagene autoleucel + Toripalimab-tpzi | Satricabtagene autoleucel Toripalimab-tpzi | 0 | 0 |